A Postzygotic KRAS Mutation in a Patient with Schimmelpenning Syndrome Presenting with Lipomatosis, Renovascular Hypertension, and Diabetes Mellitus

Overview

Journal J Hum Genet

Specialty Genetics

Date 2018 Nov 17

PMID 30443000

Citations 8

Authors

Misako Nagatsuma

Kei Takasawa

Takeru Yamauchi

Ryuichi Nakagawa

Tomoko Mizuno

Eriko Tanaka

Kouhei Yamamoto

Noriko Uemura

Kenichi Kashimada

Tomohiro Morio

Affiliations

Soon will be listed here.

Abstract

Schimmelpenning syndrome is a rare neurocutaneous disorder categorized as a mosaic RASopathy due to postzygotic HRAS or KRAS mutations. We report a 6-year-old girl diagnosed with Schimmelpenning syndrome due to a postzygotic KRAS G12D mutation. The patient had three atypical symptoms of Schimmelpenning syndrome: renovascular hypertension, congenital lipomatosis, and diabetes mellitus. The first two symptoms may overlap with phenotypes of other neurocutaneous syndromes or congenital lipomatous overgrowth syndrome due to mosaic RASopathies or other somatic mosaic mutations. We propose that impaired glucose tolerance was caused by KRAS mutation and a novel clinical phenotype of Schimmelpenning syndrome. Our study indicated that clinical diagnosis of Schimmelpenning syndrome or related conditions should be reorganized with genetic diagnosis of postzygotic mutation. Moreover, further accumulation of genetically proven cases with mosaic RASopathies should be used to more accurately characterize phenotypic presentations of this syndrome and develop a future therapeutic strategy, such as molecular-targeted therapy.

Citing Articles

Cancer in Multilineage Mosaic RASopathies due to Pathogenic Variants in HRAS or KRAS: A Systematic Review and Meta-analysis.

Windrich J, Ney G, Rosenberg P, Kim J, Zenker M, Stewart D Clin Cancer Res. 2024; 30(22):5116-5121.

PMID: 39287844 PMC: 11565173. DOI: 10.1158/1078-0432.CCR-24-1928.

Exploring New Drug Repurposing Opportunities for MEK Inhibitors in RASopathies: A Comprehensive Review of Safety, Efficacy, and Future Perspectives of Trametinib and Selumetinib.

Gazzin A, Fornari F, Cardaropoli S, Carli D, Tartaglia M, Ferrero G Life (Basel). 2024; 14(6).

PMID: 38929714 PMC: 11204468. DOI: 10.3390/life14060731.

Classification of KRAS-Activating Mutations and the Implications for Therapeutic Intervention.

Johnson C, Burkhart D, Haigis K Cancer Discov. 2022; 12(4):913-923.

PMID: 35373279 PMC: 8988514. DOI: 10.1158/2159-8290.CD-22-0035.

Oral HRAS Mutation in Orofacial Nevus Sebaceous Syndrome (Schimmelpenning-Feuerstein-Mims-Syndrome): A Case Report With a Literature Survey.

Friedrich R, Gosau M, Luebke A, Hagel C, Kohlrusch F, Hahn M In Vivo. 2022; 36(1):274-293.

PMID: 34972725 PMC: 8765160. DOI: 10.21873/invivo.12701.

Identification of a recurrent mosaic variant in brain tissue from an individual with nevus sebaceous syndrome.

Green T, MacGregor D, Carden S, Harris R, Hewitt C, Berkovic S Cold Spring Harb Mol Case Stud. 2021; 7(6).

PMID: 34649968 PMC: 8751419. DOI: 10.1101/mcs.a006133.

References

Booth T, Rollins N . MR imaging of the spine in epidermal nevus syndrome. AJNR Am J Neuroradiol. 2002; 23(9):1607-10. PMC: 7976813. View

Alsohim F, Abou-Jaoude P, Ninet J, Pracros J, Phan A, Cochat P . Bilateral renal artery stenosis and epidermal nevus syndrome in a child. Pediatr Nephrol. 2011; 26(11):2081-4. PMC: 3178020. DOI: 10.1007/s00467-011-1949-z. View

Mor A, Aizman E, George J, Kloog Y . Ras inhibition induces insulin sensitivity and glucose uptake. PLoS One. 2011; 6(6):e21712. PMC: 3126849. DOI: 10.1371/journal.pone.0021712. View

Kurek K, Luks V, Ayturk U, Alomari A, Fishman S, Spencer S . Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. Am J Hum Genet. 2012; 90(6):1108-15. PMC: 3370283. DOI: 10.1016/j.ajhg.2012.05.006. View

Groesser L, Herschberger E, Ruetten A, Ruivenkamp C, Lopriore E, Zutt M . Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome. Nat Genet. 2012; 44(7):783-7. DOI: 10.1038/ng.2316. View

Hafner C, Groesser L . Mosaic RASopathies. Cell Cycle. 2012; 12(1):43-50. PMC: 3570515. DOI: 10.4161/cc.23108. View

Chamberlain C, Scheel D, McGlynn K, Kim H, Miyatsuka T, Wang J . Menin determines K-RAS proliferative outputs in endocrine cells. J Clin Invest. 2014; 124(9):4093-101. PMC: 4153699. DOI: 10.1172/JCI69004. View

Keppler-Noreuil K, Rios J, Parker V, Semple R, Lindhurst M, Sapp J . PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation. Am J Med Genet A. 2015; 167A(2):287-95. PMC: 4480633. DOI: 10.1002/ajmg.a.36836. View

Kuroda Y, Ohashi I, Enomoto Y, Naruto T, Baba N, Tanaka Y . A postzygotic NRAS mutation in a patient with Schimmelpenning syndrome. Am J Med Genet A. 2015; 167A(9):2223-5. DOI: 10.1002/ajmg.a.37135. View

10.

Loconte D, Grossi V, Bozzao C, Forte G, Bagnulo R, Stella A . Molecular and Functional Characterization of Three Different Postzygotic Mutations in PIK3CA-Related Overgrowth Spectrum (PROS) Patients: Effects on PI3K/AKT/mTOR Signaling and Sensitivity to PIK3 Inhibitors. PLoS One. 2015; 10(4):e0123092. PMC: 4411002. DOI: 10.1371/journal.pone.0123092. View

11.

Waelchli R, Williams J, Cole T, Dattani M, Hindmarsh P, Kennedy H . Growth and hormone profiling in children with congenital melanocytic naevi. Br J Dermatol. 2015; 173(6):1471-8. PMC: 4737097. DOI: 10.1111/bjd.14091. View

12.

Watanabe Y, Shido K, Niihori T, Niizuma H, Katata Y, Iizuka C . Somatic BRAF c.1799T>A p.V600E Mosaicism syndrome characterized by a linear syringocystadenoma papilliferum, anaplastic astrocytoma, and ocular abnormalities. Am J Med Genet A. 2015; 170A(1):189-94. DOI: 10.1002/ajmg.a.37376. View

13.

Bennett J, Tan T, Alcantara D, Tetrault M, Timms A, Jensen D . Mosaic Activating Mutations in FGFR1 Cause Encephalocraniocutaneous Lipomatosis. Am J Hum Genet. 2016; 98(3):579-587. PMC: 4800051. DOI: 10.1016/j.ajhg.2016.02.006. View

14.

Boppudi S, Bogershausen N, Hove H, Percin E, Aslan D, Dvorsky R . Specific mosaic KRAS mutations affecting codon 146 cause oculoectodermal syndrome and encephalocraniocutaneous lipomatosis. Clin Genet. 2016; 90(4):334-42. DOI: 10.1111/cge.12775. View

15.

Whyte M, Griffith M, Trani L, Mumm S, Gottesman G, McAlister W . Melorheostosis: Exome sequencing of an associated dermatosis implicates postzygotic mosaicism of mutated KRAS. Bone. 2017; 101:145-155. PMC: 5518630. DOI: 10.1016/j.bone.2017.04.010. View

16.

Suzuki Y, Enokido Y, Yamada K, Inaba M, Kuwata K, Hanada N . The effect of rapamycin, NVP-BEZ235, aspirin, and metformin on PI3K/AKT/mTOR signaling pathway of PIK3CA-related overgrowth spectrum (PROS). Oncotarget. 2017; 8(28):45470-45483. PMC: 5542201. DOI: 10.18632/oncotarget.17566. View

17.

Lim Y, Moscato Z, Choate K . Mosaicism in Cutaneous Disorders. Annu Rev Genet. 2017; 51:123-141. PMC: 8026264. DOI: 10.1146/annurev-genet-121415-121955. View

18.

Rogers M, McCrossin I, Commens C . Epidermal nevi and the epidermal nevus syndrome. A review of 131 cases. J Am Acad Dermatol. 1989; 20(3):476-88. DOI: 10.1016/s0190-9622(89)70061-x. View

19.

van de Warrenburg B, van Gulik S, Renier W, Lammens M, Doelman J . The linear naevus sebaceus syndrome. Clin Neurol Neurosurg. 1998; 100(2):126-32. DOI: 10.1016/s0303-8467(98)00012-2. View